Children's Cancer Group
6
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
17%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
Role: collaborator
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
Role: collaborator
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
Role: collaborator
506U78 in Treating Patients With Refractory Hematologic Cancer
Role: collaborator
Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
Role: collaborator
Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma
Role: collaborator
All 6 trials loaded